To Evaluate the Efficacy and Safety of 'BRDE33-100' for the Temporary Correction of Moderate to Severe Nasolabial Folds

Inclusion Criteria: All of the following inclusion criteria must be met for a subject to be enrolled in this clinical trial. * Male or female subjects aged between 19 and 75 years, inclusive, as of the date of written informed consent. * Voluntarily decided to participate in the study and signed the informed consent form in writing * Subjects who desire improvement in nasolabial folds and have a Wrinkle Severity Rating Scale (WSRS) score of 3 or 4. * Subjects whose bilateral nasolabial folds appear visually symmetrical, although WSRS scores do not need to be identical on both sides. * Subjects who agree to use appropriate contraception from the date of signing the informed consent form until 3 months after the end of the clinical trial. \*Examples of acceptable contraception include: copper intrauterine device (IUD), hormone-releasing IUD, condoms, vasectomy, tubal ligation, spermicides, vaginal contraceptive film, subdermal implants, injectable contraceptives, female condoms, and oral contraceptives. * Subjects who agree not to undergo any procedures or treatments that may affect the nasolabial folds during the study period. * Subjects who are able to understand and comply with the study instructions and are available for the entire duration of the study. Exclusion Criteria: Subjects who meet any of the following exclusion criteria will not be eligible for participation in this clinical trial. * Received antithrombotic agents (except for low-dose aspirin \[100 mg, up to 3…